Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated that troxerutin may protect human dermal papilla cells from H2O2-induced damage and suggests potential in treating alopecia by inhibiting ROS-mediated cellular damage.

This review examines the physiology of skin flap necrosis and various substances studied to improve flap viability, noting that promising results are mostly from animal studies, with nitroglycerin already tested in humans.

This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.

In this study, plerixafor was found to enhance melanogenesis and promote repigmentation by engaging a β-arrestin–β-catenin–MITF signaling axis in melanocytes, and showed effectiveness in restoring depigmentation in a murine model without causing systemic toxicity.

This study found that optimal antioxidant properties of a cream-mask, as indicated by extended Paramecium caudatum motor activity in a toxic environment, were achieved with 10% Sophora japonica tincture and 5% Serenoa repens dry extract.

This study found that tribuloside, a flavonoid from Tribulus terrestris L., enhances melanin production in human melanocytes, zebrafish, and human skin samples without causing toxicity, potentially through inhibiting PDE to increase cAMP levels and promote the melanin biosynthesis pathway.

This study found that Plerixafor, a CXCR4 antagonist, promotes melanogenesis in melanocytes by increasing MITF and tyrosinase expression and enhancing melanocyte migration, and it effectively restores pigmentation in a mouse depigmentation model without toxicity, highlighting its potential for treating pigmentary disorders.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

In this study using C3H/HeJ mice, a single subcutaneous injection of the fusion protein PTH-CBD increased anagen hair follicle counts and promoted hair regrowth comparably to daily oral ruxolitinib, potentially by enhancing beta-catenin production and stimulating anagen transition.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

This review discusses the use of Dermal Papilla cells as in vitro models for studying hair growth modulators, emphasizing their role in aiding the development of new hair treatments, but reports no new clinical results.

This review examines around 68 plant sources from six major plant families, assessing their scientific rationale and use by the cosmeceutical industry for applications like anti-ageing and sun protection.

This study found that epigallocatechin-3-gallate (EGCG) may reduce paclitaxel-induced apoptosis in human dermal papilla cells by regulating microRNA expression related to apoptosis and cell proliferation.

This review investigates molecular mechanisms behind PCOS pathogenesis and discusses potential therapies, but reports no new clinical results.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

In this study, researchers investigated the use of the Pulse Booster Drug Delivery Mesojectgun technology for non-invasive treatment of scalp conditions, finding improvements in hair volume, thickness, and reduction of hair loss in four participants with alopecia after applying specific active ingredients.

Tigason improved hair growth in a boy with monilethrix without side effects.

In this case report, a 26-year-old man with alopecia universalis, resistant to multiple standard treatments, achieved complete and sustained hair regrowth with ruxolitinib, highlighting its potential as a promising option for patients with refractory AU.

In this study, a single subcutaneous dose of PTH-CBD showed similar hair regrowth to daily oral ruxolitinib in mice with alopecia, possibly through increased beta-catenin and anagen transition stimulation.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.

This study found that fractions of Tridax procumbens extract demonstrated significant antioxidant activity, comparable to standard ascorbic acid, in laboratory tests.

This study reports that topical ruxolitinib failed to induce hair growth in a 66-year-old patient with alopecia areata, highlighting the need to explore factors affecting treatment response and compare topical vs oral administration outcomes.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This study found that the retinoid LGD1069 suppressed mammary tumorigenesis in a mouse model without observable toxicity, while TTNPB showed modest effects but was associated with significant toxicity.

This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.